A diversified product portfolio (Global Products, China Rights) helps Winhealth hedge policy and industry risks and realize long-term solid growth of the enterprise.  Based on its judgment of China's policy trend and clinical needs, the company has chosen to focus on the import, development and commercialization of global innovative drugs (including orphan drugs), foreign original drugs (On or Off Patent) and complex generic drugs (technical barriers, API barriers, Bio-similar), and spend about 3 years in establishing a featured product portfolio that meetsChinese clinical needs, so as to diversify the company's products and revenue.